Hematology

Long-term emicizumab appears safe, effective in severe hemophilia A

Emicizumab in patients with severe hemophilia A was safe and effective for up to 5.8 years, regardless of inhibitor status, according to results of the phase 1 study and phase 1/2 extension study. In this study, 18 patients received emicizumab subcutaneously once per week at maintenance doses of 0.3 mg/kg,...